Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

experience delays in the conduct or completion of the PROPEL trial, whether caused by competition, adverse events, patient enrollment rates, regulatory issues or other factors; that clinical trials may not demonstrate that PDX is both safe and effective for the treatment of patients with PTCL or any other type of cancer; that data from preclinical studies and clinical trials may not be indicative of future clinical trial results; that the safety and/or efficacy results of the PROPEL trial may not support an application for marketing approval in the United States or any other country; that an application for marketing approval may not be accepted for priority review or at all by the FDA or any other regulatory authority; and that the Company may lack the financial resources and access to capital to fund future clinical trials for PDX or any of its other product candidates. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Note: The Allos logo is a trademark of Allos Therapeutics, Inc.


'/>"/>
SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- ChemImage will present a workshop focused on ... Forensic Science Society,s 22 nd International Symposium ... Australia .  Forensic Scientists will be in ... imaging can bring to examination procedures. ... Product Development at ChemImage, will host a workshop ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, ... (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing ... Company recently changed its fiscal year end to June ... its common stock on a national securities exchange in ... as filed with the United States Securities Exchange Commission ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... England, 4th May 2007 - CeNeS Pharmaceuticals plc,(LSE: ... of an independent study in the respected scientific,journal ... 5161. CeNeS,is developing CNS 5161 as a potential ... the work that CeNeS has,already undertaken with CNS ...
... - New data from a,randomized, double-blind study ... injection) along with the oral,antibiotic minocycline reduced ... 63 percent (p=0.08) in patients with active,relapsing-remitting ... imaging (MRI), compared to those receiving,COPAXONE(R) alone. ...
Cached Medicine Technology:Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:8/30/2014)... Ticket Down is a reliable ... in NYC. This popular ticket exchange has ... day session, evening session, courtside seats, grandstand seats, general ... Grand Slam Tournament. , The 2014 U.S. Open Tennis ... Tennis Championship: Men's/Women's 3rd Round - Session 11 Tickets ...
(Date:8/30/2014)... 2014 Acne is a common problem millions of ... nothing more than a daily nuisance, for some, it can have ... acne can even lead to dramatic mood swings and depression. ... to clear up their skin. In some cases, that can make ... trial and error, those on a quest for clearer skin can ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... five patients operated on for broken bones or other orthopedic ... study finds. Less-educated patients and patients who had ... be "doctor shoppers," said study lead author Dr. Brent Morris, ... said, the study suggests that doctors aren,t talking to one ...
(Date:8/30/2014)... Pittsburgh, PA (PRWEB) August 30, 2014 ... the result of a car accident," said one of ... constant muscle strain in her shoulder and neck area. ... we invented reduced pain and pressure, assisting in comfort ... for the patent-pending PILLOW CRADLE to support the head, ...
Breaking Medicine News(10 mins):Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3
... , WEDNESDAY, Aug. 17 (HealthDay News) -- ... than one-third of lower leg injuries treated in U.S. ... Alternative approaches to treatment, such as an emergency hotline ... emergency department resources, researchers from Massachusetts General Hospital in ...
... A co-worker,s rudeness can have a great impact on relationships ... published online in the Journal of Organizational Behavior . ... intense that, at the end of the day, it is ... the worker,s family and partner, who in turn takes the ...
... -- The risk of deep vein thrombosis -- a sometimes deadly ... surgery -- is low when preventive measures such as anti-clotting drugs ... cases of deep vein thrombosis, or DVT, that occur after general ... study, published in the Aug. 15 online edition of the journal ...
... back on current expenses and largely unable to meet essential ... to a new poll from The SCAN Foundation and the ... poll, in its second year, sought to better understand health ... current economic crisis and the rising number of Californians older ...
... TUESDAY, Aug. 16 (HealthDay News) -- Drinking moderate amounts ... dementia, according to a review of previous research. ... Medicine analyzed data from more than 365,000 people who ... 1977. Moderate drinkers were 23 percent less likely ...
... new study has shown the Flexible-Fiber CO2 laser to ... (TSC) without the,line of sight problems encountered with conventional ... Medical Center (BMC) and Boston University School of Medicine ... Neurosurgery . This is the first study to report ...
Cached Medicine News:Health News:Sprained Ankles Straining ER Resources, Study Finds 2Health News:Baylor University study finds consequences of co-worker rudeness are far-reaching 2Health News:Central Catheters May Raise Risk of Blood Clots After Surgery 2Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 2Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 3Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 4Health News:Moderate Drinking May Help Prevent Alzheimer's, Other Dementia 2Health News:Moderate Drinking May Help Prevent Alzheimer's, Other Dementia 3Health News:Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery 2
... an extremely accurate digital A-scan system. The ... probe and fast precise algorithm enables scan ... along the visual axis. The A5500 A-scan ... monitor, built-in thermal printer, 5 different examination ...
... is extremely portable, weighing slightly more than ... system provides a large liquid crystal display. ... noise probe and fast precise algorithm enables ... probe along the visual axis. The Microscan ...
... Accurate, efficient and easy to use. The ... variety of regressive, theoretical, and adaptive IOL ... the patient. Convenient design features improve your ... hands-free operation, audible tone to minimize corneal ...
... Ultrasonic A-Scan offers so many ... package. Besides,its compact and lightweight ... measurement and easy operation.,Furthermore, it ... and manual gate.,NIDEK is proud ...
Medicine Products: